LVOne is a rapid diagnostic test for Large Vessel Occlusion (LVO) stroke detection, delivering results in minutes with 95% accuracy. Using a proprietary combination of D-dimer and GFAP biomarkers in a lateral flow format, it enables emergency teams to identify stroke type quickly without additional ...
Manufactured by
Pockit Diagnostics Ltd - Upfront diagnostics
Cambridge, United Kingdom
UpFront Diagnostics is a MedTech company pioneering point-of-care diagnostics for critical, time-sensitive conditions. The company s lead product, LVOne, is designed to revolutionise emergency stroke care by providing immediate, actionable diagnostic information. UpFront Diagnostics is committed to transforming patient outcomes by solving the current triage gap in stroke pathways.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
ABCDx
Spain · 3 relevant products
Ezdiatech Inc
South Korea · 2 relevant products
VELLAP Diagnostics GmbH
Germany · 1 relevant product
32 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →11 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
3 of 50 closest product alternatives
ABCDx · Spain
A point-of-care diagnostic solution powered by advanced blood-based biomarkers for brain injuries. LVOCheck is designed for the selection and triage of large vessel occlusion (LVO) stroke patients to identify those requiring rapid treatment. The platform utilizes proprietary Software as a Medical Device technology to differentiate between ischemic and haemorrhagic stroke and detect mild traumatic brain injury.
Ezdiatech Inc · South Korea
Automated immunoassay system for rapid blood-based diagnosis of traumatic brain injury using dual biomarkers (GFAP and UCH-L1). The VEUS platform delivers results within 15-50 minutes with high sensitivity and multiplexing capability, utilizing magnetic particle technology for accurate point-of-care neurological assessment.
ABCDx · Spain
A rapid biochemical test that differentiates between ischemic stroke and intracranial hemorrhage within the first 4 hours from symptom onset. The test uses a combination of biomarkers to provide accurate diagnosis for stroke subtype determination, enabling rapid decision-making at point-of-care settings including ambulances and primary hospitals. This allows for timely initiation of specific treatment protocols such as reperfusion therapies.
47 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products